No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
nelarabine Sensitive: A1 - Approval
|
nelarabine Sensitive: A1 - Approval
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
No biomarker
|
T Acute Lymphoblastic Leukemia
|
prednisone + vincristine + daunorubicin + pegaspargase + nelarabine Sensitive: A2 - Guideline
|
prednisone + vincristine + daunorubicin + pegaspargase + nelarabine Sensitive: A2 - Guideline
|
TP53 mutation
|
T Acute Lymphoblastic Leukemia
|
TP53 mutation
|
T Acute Lymphoblastic Leukemia
|
venetoclax Sensitive: C1 - Off-label
|
venetoclax Sensitive: C1 - Off-label
|
NOTCH1 mutation
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 mutation
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
FBXW7 mutation
|
T Acute Lymphoblastic Leukemia
|
FBXW7 mutation
|
T Acute Lymphoblastic Leukemia
|
prednisone Resistant: C3 – Early Trials
|
prednisone Resistant: C3 – Early Trials
|
HGF-L
|
T Acute Lymphoblastic Leukemia
|
HGF-L
|
T Acute Lymphoblastic Leukemia
|
mogamulizumab Resistant: C3 – Early Trials
|
mogamulizumab Resistant: C3 – Early Trials
|
NOTCH1 L1574Q
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 L1574Q
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
NOTCH1 V1577E
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 V1577E
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
NOTCH1 L1600Q
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 L1600Q
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
NOTCH1 L1585R
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 L1585R
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
NOTCH1 V1577A
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 V1577A
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
NOTCH1 L1600P
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 L1600P
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
NOTCH1 L1574P
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 L1574P
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
NOTCH1 F1592S
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 F1592S
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
NOTCH1 F1592C
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 F1592C
|
T Acute Lymphoblastic Leukemia
|
prednisone Sensitive: C3 – Early Trials
|
prednisone Sensitive: C3 – Early Trials
|
JAK3 mutation
|
T Acute Lymphoblastic Leukemia
|
JAK3 mutation
|
T Acute Lymphoblastic Leukemia
|
tofacitinib Resistant: C4 – Case Studies
|
tofacitinib Resistant: C4 – Case Studies
|
SET-NUP214 fusion
|
T Acute Lymphoblastic Leukemia
|
SET-NUP214 fusion
|
T Acute Lymphoblastic Leukemia
|
ADE Sensitive: C4 – Case Studies
|
ADE Sensitive: C4 – Case Studies
|
FGFR1 rearrangement + Chr t(8;13)
|
T Acute Lymphoblastic Leukemia
|
FGFR1 rearrangement + Chr t(8;13)
|
T Acute Lymphoblastic Leukemia
|
Tyrosine kinase inhibitor Resistant: C4 – Case Studies
|
Tyrosine kinase inhibitor Resistant: C4 – Case Studies
|
TP53 mutation
|
T Acute Lymphoblastic Leukemia
|
TP53 mutation
|
T Acute Lymphoblastic Leukemia
|
CD7-targeted CAR-T immunotherapy Sensitive: C4 – Case Studies
|
CD7-targeted CAR-T immunotherapy Sensitive: C4 – Case Studies
|
MEF2C overexpression
|
T Acute Lymphoblastic Leukemia
|
MEF2C overexpression
|
T Acute Lymphoblastic Leukemia
|
ABT-737 Sensitive: D – Preclinical
|
ABT-737 Sensitive: D – Preclinical
|
PAK2 overexpression
|
T Acute Lymphoblastic Leukemia
|
PAK2 overexpression
|
T Acute Lymphoblastic Leukemia
|
FRAX597 + PF-3758309 Sensitive: D – Preclinical
|
FRAX597 + PF-3758309 Sensitive: D – Preclinical
|
MCL1 underexpression
|
T Acute Lymphoblastic Leukemia
|
MCL1 underexpression
|
T Acute Lymphoblastic Leukemia
|
venetoclax + BI 6727 Sensitive: D – Preclinical
|
venetoclax + BI 6727 Sensitive: D – Preclinical
|
MYC underexpression
|
T Acute Lymphoblastic Leukemia
|
MYC underexpression
|
T Acute Lymphoblastic Leukemia
|
venetoclax + BI 6727 Sensitive: D – Preclinical
|
venetoclax + BI 6727 Sensitive: D – Preclinical
|
CCND3 deletion
|
T Acute Lymphoblastic Leukemia
|
CCND3 deletion
|
T Acute Lymphoblastic Leukemia
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
JAK3 M511I
|
T Acute Lymphoblastic Leukemia
|
JAK3 M511I
|
T Acute Lymphoblastic Leukemia
|
tofacitinib XR Sensitive: D – Preclinical
|
tofacitinib XR Sensitive: D – Preclinical
|
JAK3 M511I
|
T Acute Lymphoblastic Leukemia
|
JAK3 M511I
|
T Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: D – Preclinical
|
ruxolitinib Sensitive: D – Preclinical
|
NOTCH1 mutation
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 mutation
|
T Acute Lymphoblastic Leukemia
|
CB-839 Sensitive: D – Preclinical
|
CB-839 Sensitive: D – Preclinical
|
NOTCH1 mutation
|
T Acute Lymphoblastic Leukemia
|
NOTCH1 mutation
|
T Acute Lymphoblastic Leukemia
|
IACS-010759 Sensitive: D – Preclinical
|
IACS-010759 Sensitive: D – Preclinical
|
BCL2L1 underexpression
|
T Acute Lymphoblastic Leukemia
|
BCL2L1 underexpression
|
T Acute Lymphoblastic Leukemia
|
venetoclax + BI 6727 Sensitive: D – Preclinical
|
venetoclax + BI 6727 Sensitive: D – Preclinical
|
PRC2 mutation
|
T Acute Lymphoblastic Leukemia
|
PRC2 mutation
|
T Acute Lymphoblastic Leukemia
|
JQ-1 Sensitive: D – Preclinical
|
JQ-1 Sensitive: D – Preclinical
|
PCDHB15 overexpression
|
T Acute Lymphoblastic Leukemia
|
PCDHB15 overexpression
|
T Acute Lymphoblastic Leukemia
|
ruxolitinib Sensitive: D – Preclinical
|
ruxolitinib Sensitive: D – Preclinical
|
NUP214-ABL1 rearrangement
|
T Acute Lymphoblastic Leukemia
|
NUP214-ABL1 rearrangement
|
T Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
TCRB-LCK translocation
|
T Acute Lymphoblastic Leukemia
|
TCRB-LCK translocation
|
T Acute Lymphoblastic Leukemia
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
RPL10 R98S
|
T Acute Lymphoblastic Leukemia
|
RPL10 R98S
|
T Acute Lymphoblastic Leukemia
|
venetoclax Sensitive: D – Preclinical
|
venetoclax Sensitive: D – Preclinical
|
NT5C2 R367Q
|
T Acute Lymphoblastic Leukemia
|
NT5C2 R367Q
|
T Acute Lymphoblastic Leukemia
|
mercaptopurine Resistant: D – Preclinical
|
mercaptopurine Resistant: D – Preclinical
|
CD38 expression
|
T Acute Lymphoblastic Leukemia
|
CD38 expression
|
T Acute Lymphoblastic Leukemia
|
isatuximab-irfc Sensitive: D – Preclinical
|
isatuximab-irfc Sensitive: D – Preclinical
|
DNMT3B overexpression
|
T Acute Lymphoblastic Leukemia
|
DNMT3B overexpression
|
T Acute Lymphoblastic Leukemia
|
pralatrexate Resistant: D – Preclinical
|
pralatrexate Resistant: D – Preclinical
|